Malaria Pipeline Insight

DelveInsight’s, “Malaria - Pipeline Insight, 2022,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Malaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Malaria Understanding

Malaria: Overview

Malaria is a serious, sometimes fatal, disease that is caused by a parasitic infection of the red blood cells. There are 4 kinds of malaria parasite that can infect humans: Plasmodium falciparum, which is the most serious form of malaria, and can be life-threatening; Plasmodium vivax, which is less serious and not usually life-threatening; Plasmodium ovale, which is not usually life-threatening; and Plasmodium malariae, which is not usually life-threatening. Malaria is contracted by the bite of mosquitoes. When an infected mosquito (the Anopheles mosquito) bites you, it injects the malaria parasites into your blood. These parasites then travel through the bloodstream to the liver where they multiply. During this time, when the parasites are in the liver, you will not feel ill. The parasites then leave the liver and enter the red blood cells where the parasites grow and then burst the red blood cells, allowing them to move to another blood cell. At this stage, the parasites release toxins into the bloodstream and you will begin to feel ill. The World Health Organization (WHO) estimates that each year, more than 200 million people are infected with malaria worldwide. Malaria is a common problem in areas of Asia, Africa and Central and South America. Unless precautions are taken, anyone living in or travelling to a country where malaria is present can contract the disease. The symptoms of malaria consist of fever and flu-like illness, including shaking, chills, headache, muscle aches, tiredness and a general feeling of being unwell. Because the symptoms are so general, malaria is often misdiagnosed. Nausea, vomiting and diarrhea may also be present. Malaria can also cause anaemia and jaundice (yellowing of the eyes and skin) because of the damage to the red blood cells. If not promptly treated, the most serious form of malaria (Plasmodium falciparum) may cause kidney failure, seizures, mental confusion, coma and death. For most people the symptoms of malaria will begin 7 days to 4 weeks after the mosquito bite. However, the incubation period may be longer if you have taken an inadequate course of malaria prevention medicines. Malaria is diagnosed by checking the blood for the malarial parasites (a blood film test). Malaria is treated with certain types of prescription medicines. However, the type and length of treatment depends on which kind of malaria is diagnosed, where you were infected, how old you are, and how ill you were at the start of the treatment.

 

“Malaria- Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Malaria pipeline landscape is provided which includes the disease overview and Malaria treatment guidelines. The assessment part of the report embraces, in depth Malaria commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Malaria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Malaria R&D. The therapies under development are focused on novel approaches to treat/improve Malaria. 

Malaria Emerging Drugs Chapters

This segment of the Malaria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Malaria Emerging Drugs
 

R21: GlaxoSmithKline

R21/Matrix M- the new vaccine candidate, is a modified version of RTS, S - another candidate against malaria by GlaxoSmithKline. This is designed with an aim to stop the malaria parasite- Plasmodium falciparum from entering the liver and preventing the subsequent deadly blood stages. The vaccine targets the liver stage protein of the parasite’s life cycle. It is currently in Phase III stage of development for the treatment of Malaria and is being developed by GlaxoSmithKline.

 

KAF156: Novartis

KAF156 is the first compound to progress into clinical development from the novel imidazolopiperazine class of antimalarial molecules. A key strength of the drug is its potential to both treat and prevent malaria, including resistant strains. Phase IIa studies have demonstrated that KAF156 rapidly kills both P. vivax and P. falciparum malaria parasites. It is currently in Phase II stage of development for the treatment of Malaria and is being developed by Novartis.

 

INE 963 : Novartis

INE963, which demonstrates potent cellular activity against Pf 3D7 (EC50 = 0.006 μM) and achieves "artemisinin-like" kill kinetics in vitro with a parasite clearance time of <24 h. INE963 also exhibits a high barrier to resistance in drug selection studies and a long half-life (T1/2) across species. These properties suggest the significant potential for INE963 to provide a curative therapy for uncomplicated malaria with short dosing regimens. For these reasons, INE963 was progressed through GLP toxicology studies and is now undergoing Ph1 clinical trials.


Lotilaner  : Tarsus Pharmaceuticals

Lotilaner (TP-05) as an oral formulation that is designed as a prophylactic drug against Lyme disease to eradicate the tick before it can transmit the Borrelia bacteria. TP-05 also has the potential to cause the death of mosquitos that transmit malaria. Malaria is one of the world’s highest unmet public health needs, with approximately 228 million cases and more than 400,000 deaths worldwide. Currently the drug is in pre-clinical stage of development for the treatment of Malaria.

Further product details are provided in the report……..

Malaria: Therapeutic Assessment

This segment of the report provides insights about the different Malaria drugs segregated based on following parameters that define the scope of the report, such as:

 

Major Players in Malaria

There are approx. 30+ key companies which are developing the therapies for Malaria. The companies which have their Malaria drug candidates in the most advanced stage, i.e. phase III include, GlaxoSmithKline.

 

Phases

DelveInsight’s report covers around 30+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of 
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Route of Administration

Malaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

  • Intra-articular
  • Intraocular
  • Intrathecal 
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Malaria: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Malaria therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Malaria drugs.

Malaria Report Insights

  • Malaria Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Malaria Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

  • How many companies are developing Malaria drugs?
  • How many Malaria drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Malaria?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Malaria therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Malaria and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Malaria: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Malaria– DelveInsight’s Analytical Perspective

Late Stage Products (Pre-Registration)

  • Comparative Analysis

Drug name : Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Last Stage Products (Phase III)

  • Comparative Analysis

R21: GlaxoSmithKline

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

KAF156: Novartis

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

Lotilaner  : Tarsus Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Malaria Key Companies

Malaria Key Products

Malaria - Unmet Needs

Malaria - Market Drivers and Barriers

Malaria - Future Perspectives and Conclusion

Malaria Analyst Views

Malaria Key Companies

Appendix

List of Table

Table 1: Total Products for Malaria

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Malaria

Figure 2: Late Stage Products                               

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• GlaxoSmithKline
•  Sanaria
•  Tarsus Pharmaceuticals
•  Novartis
•  Nobelpharma
•  Curevac
•  Novavax

 

 

Forward to Friend

Need A Quote